Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00019435 | LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019825 | Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00020007 | Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00707252 | Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 11 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT01914263 | Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection | unknown | Phase 1 | 40 | Alliancells-PuRui Biocience Co., Ltd.INDUSTRY | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01772732 | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2015 | clinicaltrials |
| NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 203 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 8, 2015 | clinicaltrials |
| NCT01714037 | A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC](HALO) | terminated | Phase 1 | 82 | Debiopharm International SAINDUSTRY | 3 | Apr 8, 2015 | clinicaltrials |
| NCT00346385 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 97 | ImmunoGen, Inc.INDUSTRY | 2 | Mar 26, 2015 | clinicaltrials |
| NCT00569296 | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 1 | 5 | Roger Williams Medical CenterOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT02066870 | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | unknown | Phase 1 | 9 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | terminated | Phase 1 / Phase 2 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT00441337 | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies(MDX1106-01) | completed | Phase 1 | 39 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00738751 | Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers | completed | Phase 1 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT01683682 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)(VENUS-2) | completed | Phase 1 | 8 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT01386580 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | completed | Phase 1 / Phase 2 | 84 | BBB-Therapeutics B.V.INDUSTRY | 4 | Jan 22, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | terminated | Phase 1 | 126 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01160731 | Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Cancer Trials IrelandNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT01324492 | Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor(\MACS1304) | completed | Phase 1 | 16 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01700400 | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | completed | Phase 1 | 13 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01799161 | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Eckhard PodackOTHER | 0 | Nov 17, 2014 | clinicaltrials |
| NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT01611584 | A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00108186 | Celecoxib Treatment for Lung Cancer | withdrawn | Phase 1 | 0 | US Department of Veterans AffairsFED | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00088959 | Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2014 | clinicaltrials |
| NCT01426841 | Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer | unknown | Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00056537 | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer | completed | Phase 1 | 44 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT00132379 | ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 13 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT02211833 | Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer | completed | Phase 1 | 41 | Boehringer IngelheimINDUSTRY | 0 | Aug 8, 2014 | clinicaltrials |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 11 | Brown UniversityOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT02204059 | Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Jul 30, 2014 | clinicaltrials |
| NCT01938456 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Jul 28, 2014 | clinicaltrials |
| NCT02199886 | Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection | terminated | Phase 1 | 6 | Boehringer IngelheimINDUSTRY | 0 | Jul 25, 2014 | clinicaltrials |
| NCT01165216 | Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2014 | clinicaltrials |
| NCT02182102 | Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer | completed | Phase 1 | 26 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02182232 | A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT00325494 | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | completed | Phase 1 | 24 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00313599 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | University of California, San FranciscoOTHER | 1 | Jul 2, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Apr 29, 2015source: clinicaltrials